Tag: bronchodilators market forecast

  • 2024 Bronchodilators Market Overview: Key Insights on Size, Share, and Trends

    2024 Bronchodilators Market Overview: Key Insights on Size, Share, and Trends

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What is the Expected Growth Rate of the Bronchodilators Market from 2024 to 2033?
    The bronchodilators market is set to grow from $30.43 billion in 2023 to $32.93 billion in 2024, achieving a CAGR of 8.2%. Contributing factors include the growing elderly population, rising asthma cases, government funding, an aging population, and increasing global air pollution.

    The bronchodilators market is anticipated to see strong growth, reaching $43.25 billion by 2028, with a CAGR of 7.0%. Factors driving this growth include the increasing prevalence of COPD, greater awareness of lung disease treatments, rising disposable incomes, and smoking rates. Major trends include advanced clinical research, technological innovations, and a rising number of patients with respiratory conditions.

    Claim Your Free Sample of the Global Bronchodilators Market Report Today!
    https://www.thebusinessresearchcompany.com/sample.aspx?id=13816&type=smp

    What Key Factors Are Fueling the Growth of the Bronchodilators Market?
    The bronchodilator market is expected to grow with the increasing prevalence of chronic obstructive pulmonary disease (COPD). Bronchodilators help alleviate airway obstruction, making breathing easier for patients. A report by Public Health Scotland noted rising COPD rates in 2023, reflecting the ongoing health challenge. Hence, the growing incidence of COPD is propelling the bronchodilator market.

    What Are the Major Segments of the Bronchodilators Market?
    1) By Type: Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Other Types
    2) By Route of Administration: Oral, Nasal (Inhalation), Injectable
    3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Other Indications
    4) By End-User: Hospitals, Specialty Clinics, Other End Users

    What New Trends Are Transforming the Bronchodilators Market?
    In the bronchodilator market, major companies are focused on innovative products like fixed-dose triple-drug combinations to better serve patients. An example is Lupin’s DIFIZMA, launched in January 2023, which combines indacaterol, glycopyrronium, and mometasone for asthma management. Approved by the Drug Controller General of India, it enhances lung function and symptom control.

    Order Now for Fast Delivery of Your Bronchodilators Market Report!
    https://www.thebusinessresearchcompany.com/report/bronchodilators-global-market-report

    Which Regions Are Driving Growth in the Bronchodilators Market?
    North America was the largest region in the bronchodilators market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Bronchodilators Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the bronchodilators market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Bronchodilators Market Include
    1. Bronchodilators Market Executive Summary
    2. Bronchodilators Market Segments
    3. Bronchodilators Market Size And Template Market Growth Rate
    4. Key Bronchodilators Market Trends
    5. Major Bronchodilators Market Drivers
    ……
    25. Key Mergers And Acquisitions In The Bronchodilators Market
    26. Top Bronchodilators Companies
    27. Bronchodilators Market Opportunities And Strategies
    28. Bronchodilators Market, Conclusions And Recommendations
    29. Appendix

    Discover Related Reports by The Business Research Company:
    Antiparasitic Drugs Global Market Report 2024
    https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

    Congenital Diaphragmatic Hernia Drugs Global Market Report 2024
    https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

    Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024
    https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

    Learn More About The Business Research Company
    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Trends And Drivers In The Bronchodilators Market 2024

    Key Trends And Drivers In The Bronchodilators Market 2024

    The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

    Impressive Historical Growth

    • Market Size: Increased from $30.43 billion in 2023 to $32.93 billion in 2024.
    • CAGR: 8.2%.
    • Key Drivers:
      • Growing geriatric population.
      • Rising incidence of asthma.
      • Increased funding by government organizations.
      • Aging population.
      • Increasing air pollution worldwide.

    Strong Future Outlook

    • Expected Growth: Projected to reach $43.25 billion by 2028.
    • CAGR: 7.0%.
    • Key Drivers:
      • Increasing prevalence of COPD.
      • Rising awareness about lung disease treatments.
      • Escalating research and development efforts.
      • Increased prevalence of pulmonary disorders.
      • Rising disposable income.
      • Increasing smoking rates.

    Read More On The Bronchodilators Market Report 2024 – https://www.thebusinessresearchcompany.com/report/bronchodilators-global-market-report

    Key Trends Shaping the Future

    • Trends:
      • Advanced clinical research and innovative strategies.
      • Growing technological advancements.
      • High prevalence of lung diseases such as COPD and asthma.
      • New product launches.
      • Rising number of patients with acute respiratory infections.

    Rising COPD Prevalence Fuels Growth in Bronchodilator Market

    • Increasing Prevalence of COPD:
      • Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by chronic inflammation of the airways and obstruction or limitation of airflow.
      • Bronchodilators are used in COPD to relax the muscles around the airways, helping to open them and make it easier to breathe.
    • Statistics: According to a report by the Scottish Public Health Observatory, COPD rates increased in males from 83.2 to 97.6 cases per 100,000, and in females from 72.6 to 97.3 as the impact of COVID-19 eased in March 2023.

    Major Players in the Bronchodilators Market

    • Key Companies:
      • Pfizer Inc.
      • Johnson & Johnson Services Inc.
      • Hoffmann-La Roche Ltd.
      • Bayer AG
      • Novartis AG
      • Thermo Fisher Scientific
      • Abbott Laboratories
      • Sanofi S.A.
      • GlaxoSmithKline plc
      • Siemens Healthcare GmbH
      • Merck & Co. Inc.
      • AstraZeneca plc
      • Teva Pharmaceuticals Industries Ltd.
      • Mylan N.V.
      • Quest Diagnostics Incorporated.
      • Boehringer Ingelheim International GmbH

    Lupin Introduces DIFIZMA: A Groundbreaking Fixed-Dose Triple Drug Combination

    • Innovative Product Launch:
      • Major companies in the bronchodilator market are developing innovative products like fixed-dose triple-drug combinations.
      • Example: In January 2023, Lupin launched DIFIZMA, a fixed-dose triple-drug bronchodilator with a combination of indacaterol, glycopyrronium, and mometasone for managing asthma.
      • DIFIZMA is offered as a dry powder inhalation and is the only fixed-dose combination approved by the Drug Controller General of India (DCGI) for treating inadequately controlled asthma by improving lung function, providing better symptom control, and reducing exacerbations.

    AstraZeneca’s Focus on Bronchodilator Products Through CinCor Pharma Acquisition

    • Strategic Acquisition:
      • In February 2023, AstraZeneca plc acquired CinCor Pharma Inc. for $1.8 billion.
      • Objective: Develop novel treatments for uncontrolled hypertension and chronic kidney disease and strengthen AstraZeneca’s respiratory portfolio, which includes several bronchodilator products.
      • CinCor Pharma: A US-based clinical-stage biopharmaceutical company involved in the development of bronchodilator-related products.

    Market Segmentation

    • By Type:
      • Beta-Adrenergic Bronchodilators
      • Anticholinergic Bronchodilators
      • Xanthine Derivatives
      • Other Types.
    • By Route of Administration:
      • Oral
      • Nasal (Inhalation)
    • By Indication:
      • Asthma
      • Chronic Obstructive Pulmonary Disease (COPD)
      • Allergic Reactions
      • Breathing Problem
      • Other Indications.
    • By End User:
      • Hospitals
      • Specialty Clinics
      • Other End Users.

    Regional Insights

    • Largest Region (2023): North America.
    • Fastest-Growing Region (Forecast Period): Asia-Pacific.

    Request for A Sample Of The Global Bronchodilators Market Report:
    https://www.thebusinessresearchcompany.com/sample_request?id=13816&type=smp